AstraZeneca settles FCPA case with SEC for $5.5M
Biopharmaceutical-company AstraZeneca has reached a $5.5 million settlement with the SEC to settle claims that it violated the Foreign Corrupt Practices Act by making improper payments to state-controlled healthcare providers in China and Russia. Jaclyn Jaeger reports.
Related articles
-
WebcastSept 23 | Decoding DOJ’s Recent Guidance on FCPA Enforcement
Join this timely and practical webinar as we break down the DOJ’s latest FCPA guidance and explore what these developments mean for compliance programs in the real world.
-
WebcastCPE Webcast: White Collar Crime Enforcement Trends in Compliance in 2025
Join a fireside chat with Kenneth Polite Jr., partner at the law firm Sidley, who served as the Assistant Attorney General for the Criminal Division of the United States Department of Justice (DOJ) from 2021-23.
-
PremiumEmerging Compliance Risks 2025: Laurie Waddy on Leadership, Anticorruption, and AI
Former Head of Compliance/Chief Compliance Officer Laurie Waddy believes compliance professionals are well-positioned to support artificial intelligence (AI) adoption in their organizations. Drawing on 25 years’ experience in legal and compliance roles across multiple industries, Waddy shares insights into top compliance trends confronting the profession, including the emerging compliance risks ...